Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants
Portfolio Pulse from Vandana Singh
Healthcare providers are facing challenges in offering Pfizer's Abrysvo and Sanofi's Beyfortus, treatments for respiratory syncytial virus (RSV) in infants, due to insurance coverage issues and high costs. RSV is a significant threat to newborns, seniors, and adults with chronic conditions. The only previous preventative measure was Swedish Orphan Biovitrum's Synagis, costing about $1,000 per dose. Abrysvo and Beyfortus reduce the risk of severe disease or hospitalization by over 50%.
October 16, 2023 | 4:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AstraZeneca, as a partner of Sanofi in Beyfortus, could also be affected by the same challenges.
As a partner of Sanofi in Beyfortus, AstraZeneca could also face potential impacts on its revenues and stock price due to the high cost and insurance coverage issues of the treatment.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60
NEGATIVE IMPACT
Swedish Orphan Biovitrum's Synagis, the only previous preventative measure for RSV, could face competition from Abrysvo and Beyfortus.
The introduction of Abrysvo and Beyfortus could pose a threat to the sales of Synagis, potentially affecting Swedish Orphan Biovitrum's revenues and stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60
NEGATIVE IMPACT
Pfizer's Abrysvo faces insurance and cost challenges, potentially affecting its distribution and sales.
The high cost and insurance coverage issues of Abrysvo could limit its accessibility, potentially affecting Pfizer's revenues and stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Sanofi's Beyfortus faces similar challenges as Pfizer's Abrysvo, which could affect its distribution and sales.
The high cost and insurance coverage issues of Beyfortus could limit its accessibility, potentially affecting Sanofi's revenues and stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80